Liver Transplantation After ex Vivo Liver Perfusion (EVOLVE)

Inclusion Criteria: Signed informed consent ≥ 18 years Indication for liver transplantation (one criteria must be met): Colorectal cancer patients who have received 1st and 2nd line chemotherapy where the treatment has been stopped due to progression or toxicity and the patient is not eligible for SECA-2 (Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases) study. Hepatocellular carcinoma patients who are not suitable for standard liver transplantation, liver resection or local treatment (Transarterial Chemoembolisation or Selective internal radiotherapy). The patients must have progression or intolerance (toxicity) for immune checkpoint inhibitors or 1st line treatment. Cholangiocarcinoma patients who have progression or intolerance to first-line chemotherapy. Benign liver disease with urgent need for transplantation within months, but no regular graft is available. Life expectancy ≤ 6 months Willing, able and expected cooperation to attend follow-up examinations Patients who have a need for liver transplantation but cannot participate in other transplant studies or participation in another clinical trial with randomization to liver transplantation. For malignant disease the following criteria must be met: Good performance status assessed at the discretion of the treating physician. ECOG (Eastern Cooperative Oncology Group) 0 or 1 Satisfactory blood tests Hemoglobin >8 g/dl Neutrophiles >1.0 (after any Granulocyte colony-stimulating factor) Platelets >75 Bilirubin <1.5 x upper normal level ASAT (Aspartate aminotransferase), ALAT (alanine aminotransferase) <5 x upper normal level Albumin above lower normal level. Exclusion Criteria: Already listed for ordinary Ltx with expectance of getting offered a regular liver graft within a reasonable time-frame. Patients included in the control arm of the SECA-3 study or the Excalibur studies except for the Ltx arm of the Excalibur I study. Mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial. Any reason why, in the opinion of the investigator, the patient should not participate.